PMID- 36198626
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221020
IS  - 2005-3894 (Electronic)
IS  - 1013-9087 (Print)
IS  - 1013-9087 (Linking)
VI  - 34
IP  - 5
DP  - 2022 Oct
TI  - Long-Term Effectiveness and Safety of Dutasteride versus Finasteride in Patients 
      with Male Androgenic Alopecia in South Korea: A Multicentre Chart Review Study.
PG  - 349-359
LID - 10.5021/ad.22.027 [doi]
AB  - BACKGROUND: Dutasteride improves hair growth compared with finasteride in male 
      androgenic alopecia (AGA) and is well tolerated. However, real-world evidence for 
      long-term dutasteride use in AGA is lacking. OBJECTIVE: To describe baseline 
      characteristics, treatment patterns and long-term safety and effectiveness of 
      dutasteride versus finasteride. METHODS: This was a multicentre, retrospective 
      medical chart review study conducted in South Korea. The index date was the first 
      prescription of dutasteride or finasteride. Baseline characteristics were 
      assessed 6 months prior to index. Safety and effectiveness (improvements in basic 
      and specific [BASP] classification) data were collected from index throughout the 
      observation period. RESULTS: Overall, 600 male adult patients were included 
      (dutasteride, n=295; finasteride, n=305). Dutasteride-treated patients were older 
      (p<0.001) and more likely to have moderate/severe BASP classification at baseline 
      (p=0.010) compared with finasteride-treated patients. Among patients treated with 
      recommended, on-label dosing exclusively (n=535: dutasteride, n=250; finasteride, 
      n=285), dutasteride-treated patients showed greater improvement in hair growth 
      than finasteride-treated patients, as measured by the BASP basic M classification 
      (adjusted incidence rate ratio [95% confidence interval]: 2.06 [1.08, 3.95]; 
      p=0.029). Among this same subset, overall occurrence of adverse events (AEs) 
      during the observation period were not statistically equivalent between groups 
      (dutasteride 7.6%, finasteride 10.5%; p=0.201), although reports of AEs of 
      special interest were equivalent (p<0.001). CONCLUSION: Dutasteride showed 
      greater effectiveness than finasteride in improving BASP classification in 
      treating male AGA and had a similar or possibly lower occurrence of overall AEs. 
      Dutasteride may provide an effective and safe treatment option for male patients 
      with AGA.
CI  - Copyright (c) The Korean Dermatological Association and The Korean Society for 
      Investigative Dermatology.
FAU - Choi, Gwang-Seong
AU  - Choi GS
AUID- ORCID: 0000-0002-5766-0179
AD  - Department of Dermatology, Inha University College of Medicine, Incheon, Korea.
FAU - Sim, Woo-Young
AU  - Sim WY
AUID- ORCID: 0000-0001-5300-6869
AD  - Department of Dermatology, Kyung Hee University Hospital at Gangdong, Seoul, 
      Korea.
FAU - Kang, Hoon
AU  - Kang H
AUID- ORCID: 0000-0002-9822-4760
AD  - Department of Dermatology, Eunpyeong St. Mary's Hospital, College of Medicine, 
      The Catholic University of Korea, Seoul, Korea.
FAU - Huh, Chang Hun
AU  - Huh CH
AUID- ORCID: 0000-0003-3944-7777
AD  - Department of Dermatology, Seoul National University Bundang Hospital, Seongnam, 
      Korea.
FAU - Lee, Yang Won
AU  - Lee YW
AUID- ORCID: 0000-0003-1268-1248
AD  - Department of Dermatology, Konkuk University School of Medicine, Seoul, Korea.
FAU - Shantakumar, Sumitra
AU  - Shantakumar S
AUID- ORCID: 0000-0001-5814-6465
AD  - Vaccines R&D, Medical Affairs, GSK, Singapore.
FAU - Ho, Yu-Fan
AU  - Ho YF
AUID- ORCID: 0000-0003-1943-5533
AD  - Vaccines R&D, Medical Affairs, GSK, Singapore.
FAU - Oh, Eun-Jeong
AU  - Oh EJ
AUID- ORCID: 0000-0001-5263-9867
AD  - GSK, Seoul, Korea.
FAU - Duh, Mei Sheng
AU  - Duh MS
AUID- ORCID: 0000-0001-5035-6687
AD  - Analysis Group, Inc., Boston, MA, United States.
FAU - Cheng, Wendy Y
AU  - Cheng WY
AUID- ORCID: 0000-0002-8281-2496
AD  - Analysis Group, Inc., Boston, MA, United States.
FAU - Bobbili, Priyanka
AU  - Bobbili P
AUID- ORCID: 0000-0002-1343-8314
AD  - Analysis Group, Inc., Boston, MA, United States.
FAU - Thompson-Leduc, Philippe
AU  - Thompson-Leduc P
AUID- ORCID: 0000-0001-9047-3941
AD  - Analysis Group, Inc., Boston, MA, United States.
FAU - Ong, Gary
AU  - Ong G
AUID- ORCID: 0000-0002-3505-2877
AD  - Pharma Research and Development, Global Medical, GSK, Singapore. 
      gary.p.ong@gsk.com.
LA  - eng
GR  - 206807/GSK/United States of America
PT  - Journal Article
PL  - Korea (South)
TA  - Ann Dermatol
JT  - Annals of dermatology
JID - 8916577
PMC - PMC9561294
OTO - NOTNLM
OT  - Alopecia
OT  - Androgenic alopecia
OT  - Dutasteride
OT  - Epidemiology
OT  - Finasteride
OT  - Retrospective studies
COIS- GSC, WYS, HK, CHH, YWL have no, real or perceived, direct or indirect conflicts 
      of interest that relate to this manuscript. GO, SS, YFH and EJO are employees of 
      GSK; GO, SS, and YFH hold stocks and shares in the company. MSD, WYC, PB and PTL 
      are employees of Analysis Group, Inc., a consulting firm that has received 
      funding for the conduct of this study.
EDAT- 2022/10/06 06:00
MHDA- 2022/10/06 06:01
PMCR- 2022/10/01
CRDT- 2022/10/05 22:14
PHST- 2022/02/15 00:00 [received]
PHST- 2022/04/27 00:00 [revised]
PHST- 2022/05/17 00:00 [accepted]
PHST- 2022/10/05 22:14 [entrez]
PHST- 2022/10/06 06:00 [pubmed]
PHST- 2022/10/06 06:01 [medline]
PHST- 2022/10/01 00:00 [pmc-release]
AID - 34.349 [pii]
AID - 10.5021/ad.22.027 [doi]
PST - ppublish
SO  - Ann Dermatol. 2022 Oct;34(5):349-359. doi: 10.5021/ad.22.027.